Trastuzumab is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody that binds HER2 and is approved for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer (1,2). The gene discussed is ERBB2; the disease is breast carcinoma.